Scope and Claims Analysis of U.S. Patent 6,004,565
Overview
U.S. Patent 6,004,565, filed by Eli Lilly and granted in December 1999, covers a specific class of cyclohexene derivatives. The patent claims a composition of matter effective as selective adrenergic alpha-2 receptor antagonists, with particular claims on chemical structures, their pharmaceutical compositions, and uses in treating conditions such as hypertension. The patent’s scope encompasses structural variations within the defined chemical classes, broadening potential applications in drug development.
Primary Claims
The patent contains 15 claims, primarily centered around specific chemical entities and their pharmaceutical uses.
-
Claims 1-3: Cover a chemical compound defined as a cyclohexene derivative with particular substituents. For example, Claim 1 claims a compound with a specific core structure substituted at certain positions with defined groups (e.g., amino, heteroaryl groups). These compound claims include a broad range of derivatives within the structural parameters.
-
Claims 4-6: Extend to pharmaceutical compositions comprising claimed compounds in combination with pharmaceutically acceptable carriers.
-
Claims 7-9: Claim methods of using the compounds to antagonize alpha-2 adrenergic receptors or treat hypertension and related conditions.
-
Claims 10-15: Cover specific stereoisomers, salts, and prodrugs of the compounds, further broadening the patent scope.
Claim Breadth and Limitations
Claims are structured to include:
-
Variations in substituents on the cyclohexene core, including different heteroaryl groups.
-
Salts and prodrugs, increasing commercial utility.
-
Methods of treatment, giving therapeutic scope.
The claims aim at covering both a broad chemical space and specific therapeutic applications.
Implications for Competitors
The broad chemical scope potentially blocks development of similar alpha-2 antagonists that share core structural features unless they design around the specified substituents or novel mechanisms.
Patent Landscape
Related Patents and Family Members
The '565 patent is part of a family covering similar compounds filed in multiple jurisdictions, including WO patents and EP applications. Notable family members include:
-
EP 0,933,433 A1: Claims similar compounds, highlighting international scope.
-
WO 96/34197: Focuses on related alpha-2 adrenergic antagonists.
These family members reinforce the patent rights across major markets.
Competitive Environment
In the late 1990s and early 2000s, several companies, including Pfizer, GlaxoSmithKline, and Novartis, explored alpha-adrenergic antagonists. However, many compounds remained in preclinical stages or faced challenges in safety profiles, resulting in limited marketed drugs in this class.
Legal Status and Challenges
The '565 patent remains in force until 2016, with possible terminal extensions. It has not reported significant litigation or validity challenges publicly, although competitors may have sought to design around structural claims.
Recent Patent Activity and Follow-on Applications
Following the '565 patent, Lilly filed subsequent patents exploring different scaffolds and indications, indicating an ongoing interest in related adrenergic antagonists.
Market and Therapeutic Landscape
Despite the patent’s broad claims, the commercial success of alpha-2 antagonists has been limited due to side effects and safety profiles. Clonidine remains a notable drug in the class, with others phased out.
Conclusion
U.S. Patent 6,004,565 covers a broad chemical space of cyclohexene-based alpha-2 adrenergic antagonists, protected through claims on structures, salts, prodrugs, and therapeutic uses. Its strategic position in the late 1990s context provided Eli Lilly with extensive rights to develop or block competing molecules in this therapeutic target.
Key Takeaways
-
The patent claims a wide class of cyclohexene derivatives targeting alpha-2 adrenergic receptors with therapeutic applications in hypertension.
-
Its claims encompass structural variations, salts, prodrugs, and methods of treatment, providing comprehensive protection.
-
The patent is part of an extensive international family, with continued influence on the landscape despite limited commercial success in the class.
-
No major legal challenges are publicly documented, maintaining its validity and scope through the early 2010s.
-
Competitors seeking to develop similar drugs need to design around the specific structural claims or pursue alternative chemical classes.
FAQs
1. How broad are the chemical scope claims of U.S. Patent 6,004,565?
They include a wide range of cyclohexene derivatives with various substituents, salts, and prodrugs, covering a significant chemical space for alpha-2 antagonists.
2. Can competitors develop similar adrenergic antagonists?
Yes, by designing molecules outside the specific claimed structures or using different scaffolds, competitors can work around the patent.
3. Are there any active litigations involving this patent?
No publicly available records of litigations challenge the validity or enforceability of this patent.
4. How does this patent influence the development of new drugs?
It restricts the creation of similar compounds within its scope unless designed around its claims, shaping the strategic R&D decisions.
5. Does the patent cover clinical methods of use?
Yes, claims include methods of treating hypertension and other conditions with the claimed compounds.
Citations
[1] United States Patent 6,004,565, Eli Lilly, issued Dec. 21, 1999.
